Evidence map›Paper›PMID 36406407›Full record

ArticleFrontiers in microbiology2022

Dual-gene detection in a single-tube system based on CRISPR-Cas12a/Cas13a for severe fever thrombocytopenia syndrome virus.

Yating Zhu, Chen Xing, Li Yang, Qian Li, Xiaofeng Wang, Jing Zhou, Cong Zhang, Cuiping Ren, Fahu Liu, Jun He and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Quantitative and modularized CRISPR/dCas9-dCpf1 dual function system inFrontiers in bioengineering and biotechnology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Yating ZhuSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Chen XingSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Li YangSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Qian LiSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Xiaofeng WangSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Jing ZhouDepartment of Clinical Laboratory, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, China.
Cong ZhangSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Cuiping RenSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Fahu LiuDepartment of Clinical Laboratory, The Affiliated Yijishan Hospital of Wannan Medical College, Wuhu, China.
Jun HeMicrobiological Laboratory, Anhui Center for Disease Control and Prevention, Hefei, China.
Bing ShenSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Yinan DuSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Yan LiuSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Anhui Medical University · CNAnhui Provincial Center for Disease Control and Prevention · CNWannan Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease, which is caused by severe fever with thrombocytopenia syndrome virus (SFTSV). The disease results in high mortality and increased morbidity and threatens global public health. Rapid detection of SFTSV is crucial for epidemic prevention in low-resource settings. Here we developed deployable, sensitive and rapid detection methods based on CRISPR/Cas12a or Cas13a technologies. The CRISPR/Cas12a-based detection assay could stably detect the SFTSV L or M genes at 10 cp/μl. The Cas13a-based method could detect the L gene as low as 0.75 cp/μl. For point-of-care testing, we combined fluorescence visualization and lateral flow detection with CRISPR/Cas-based assays. Furthermore, using the orthogonal DNA/RNA collateral activity of the Cas12a/Cas13a system, we present the dual-gene detection platform for SFTSV, which can simultaneously detect the L and M genes in a single tube. Based on the dual-gene detection, we designed multiplexed test strips to detect SFTSV. All our methods were initially validated using 52 clinical samples, showing 100% sensitivity and specificity. These new CRISPR/Cas-based detection methods are promising candidates for on-site detection of SFTSV.

Indexed as

CRISPR/Cas12aCRISPR/Cas13amultiplex detectionpoint-of-care testingSFTSV

Identifiers

PMID36406407
PMCPMC9668895
OpenAlexW4307986961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.